Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of trastuzumab emtansine vs physician's choice in HER2-positive metastatic breast cancer
2011-000509-29Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2011
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab emtansine in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival by investigator assessment. Started Jul 2011; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2011-000509-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000509-29.